Drug intelligence / Profile preview

KimerApt

Development stage: Preclinical
Lead developer: Regen BioPharma
Modality: RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

KimerApt is an aptamer-based therapeutic developed by Regen Biopharma. Aptamers are short, single-stranded DNA or RNA molecules that can bind to specific targets, functioning similarly to antibodies. The design of KimerApt incorporates dual functionality—receptor inhibition and targeted gene inhibition via siRNA delivery. This platform technology is intended for use in oncology, specifically targeting solid tumors (neoplasms). The mechanism involves both direct receptor blockade and the delivery of gene-silencing agents to inhibit genes implicated in tumor growth and immune evasion[1][3].

Targets

NR2F6 (Nuclear receptor subfamily 2 group F member 6)

Beyond the preview

Go deeper on KimerApt.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KimerApt.

Explore the full profile